Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06393465 · ClinicalTrials.gov registry record
Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy
A clinical trial of Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), sponsored by Pfizer.
- Active
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT06393465: Active study of Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), sponsored by Pfizer.
NCT06393465 is a study of Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 50 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06393465, a study of Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine the clinical effectiveness of Tafamidis in patients with Mixed Phenotype Transthyretin Amyloidosis using data that already exist in patients' medical records
Primary Outcome
Describe and compare the rate of neurologic disease progression before and after initiation of tafamidis in patients with mixed-phenotype ATTR-CM receiving tafamidis 61 mg daily in a real world setting.
Conditions Studied
Interventions
- DRUG Tafamidis
Study Locations (1)
New York
- Pfizer - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-06-15 |
| Est. Completion | 2026-02-20 |
What the registry record for NCT06393465 still lists
NCT06393465 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target.
The record links to 1 condition, with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) appearing as the primary indexed condition, and to 1 intervention - of which Tafamidis is the first listed.
NCT06393465 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06393465 about?
NCT06393465 is a clinical study titled "Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy". This study will examine the clinical effectiveness of Tafamidis in patients with Mixed Phenotype Transthyretin Amyloidosis using data that already exist in patients' medical records
What is the current status of trial NCT06393465?
This trial is currently active not recruiting. The enrollment target is 50 participants. The study started on 2024-06-15. Estimated completion is 2026-02-20.
What conditions does trial NCT06393465 study?
This clinical trial studies the following conditions: Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM).
What interventions are being tested in trial NCT06393465?
The interventions under investigation include: Tafamidis (DRUG).
Who is sponsoring clinical trial NCT06393465?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06393465 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI